PSA

PCA3 Beats PSA in Predicting Prostate Biopsy Outcomes

Jody A. Charnow March 05, 2010

SAN FRANCISCO—The prostate cancer gene 3 (PCA3) molecular urine test is more accurate than the PSA test in predicting outcomes of repeat biopsies, new findings confirm.
 

PSA Levels Decline After The Start of Statin Therapy

Jody A. Charnow January 15, 2010

Onset of statin use is associated with a significant reduction in serum PSA level, data suggest.
 

PSA Testing Rate Highest in Blacks

Jody A. Charnow December 15, 2009

A study of a large multiethnic cohort found that African-American men had a higher prevalence of PSA screening than white and Latino men.
 

Undetectable PSA Possible With Radiation

John Schieszer December 10, 2009

After a median of 32 months, PSA was undetectable in 12% of patients.
 

BMI Affects PSA Test Results in Whites

Jody A. Charnow September 18, 2009

The likelihood of an abnormal finding is 46% lower in obese men than normal-weight men, study shows
 

PSM Site Predicts PSA Relapse Risk

Jody A. Charnow September 17, 2009

Positive margins at the prostate base are associated with the worst outcomes.
 

Adenovirus/PSA Vaccine Shows Promise

John Schieszer September 17, 2009

Researchers observe positive T cell responses in men with nonmetastatic recurrence prostate cancer.
 

PSADT Predicts Mortality

Jody A. Charnow July 22, 2009

Among men who experience PSA recurrence following radical prostatectomy (RP) for prostate cancer, a PSA doubling time (PSADT) of less than nine months at the time of recurrence is associated with a significantly increased risk of death, according to a study.
 

PSAs of 1.5-4 Hike PCa Risk

Jody A. Charnow July 13, 2009

ORLANDO—Men with PSA values of 1.5-4 ng/mL have a significantly elevated four-year risk of being diagnosed with prostate cancer compared with men who have PSA levels below 1.5, according to a retrospective study of 21,502 men.
 

Statins May Prevent PSA Relapse

Jody A. Charnow June 30, 2009

Prostate cancer patients who use statins may be at lower risk of PSA recurrence after radical prostatectomy (RP) compared with those who do not use the medications, according to investigators.
 

Statins May Prevent PSA Relapse

Jody A. Charnow June 30, 2009

TORONTO—Prostate cancer patients who use statins may be at lower risk of PSA recurrence after radical prostatectomy (RP) compared with those who do not use the medications, according to investigators.
 

Study Defines PCa Metastasis Predictors

Jody A. Charnow June 18, 2009

PSA DOUBLING time (PSADT), Gleason score, and time to PSA progression are strong independent predictors of metastasis-free survival in prostate cancer patients who experience PSA recurrence following radical prostatectomy (RP).
 

Soy Well-Tolerated in PCa Patients

John Schieszer June 18, 2009

DENVER - Consuming 20 g of soy daily for up to two years is safe and may be beneficial for men at high risk for biochemical failure after radical prostatectomy, according to preliminary findings from an ongoing study.
 

Delayed PSA Recurrence a Good Sign

Jody A. Charnow June 16, 2009

PSA recurrence (PSAR) more than five years after radical prostatectomy for prostate cancer is associated with better cancer-specific survival than PSAR less than five years after surgery, a study found.
 

Pomegranate Juice May Help Prostate Cancer Patients

Jody A. Charnow May 28, 2009

Pomegranate juice may help slow progression of prostate cancer in men who experience rising PSA levels following radical prostatectomy or radiotherapy, data suggest.
 

PSA Screening Cuts Prostate Cancer Death Risk

Jody A. Charnow May 01, 2009

PSA screening for prostate cancer is associated with a 20% reduction in mortality from the disease, according to findings from the largest prostate cancer study ever conducted.
 

PSA Density Predicts Worse Prostate Cancer Pathology

Jody A. Charnow April 29, 2009

PSA density (PSAD) predicts pathologic upstaging following radical prostatectomy (RP) for prostate cancer, a study found.
 

PSA Density Predicts Worse Prostate Cancer Pathology

Jody A. Charnow April 28, 2009

CHICAGO—PSA density (PSAD) predicts pathologic upstaging following radical prostatectomy (RP) for prostate cancer, a study found.
 

AUA: Start Offering PSA Testing to Men at Age 40

April 27, 2009

The American Urological Association (AUA) recommends that PSA testing should be offered to well-informed men aged 40 years and older who have a life expectancy of at least 10 years.
 

New AUA Recommendation: Start Offering PSA Testing at 40

Jody A. Charnow April 27, 2009

CHICAGO—The American Urological Association (AUA) recommends that PSA testing should be offered to well-informed men aged 40 years and older who have a life expectancy of at least 10 years.
 

PSA Is Not Enough to Assess Prostate Cancer Risk

John Schieszer April 17, 2009

Canadian researchers say it may be time to move beyond PSA-based predictions of prostate cancer risk. New technology and gene-based markers make it possible to use a more individualized approach that considers all prostate cancer risk factors.
 

Prostate Cancer Possible Even if PSA Declines

Jody A. Charnow March 23, 2009

Men whose PSA levels rise above 4 ng/mL—a commonly used threshold for prostate biopsy—but then decline to below this level can still harbor prostate cancer, and many of these cancers may be aggressive.
 

Prebiopsy Antibiotics May Be Unjustified

Jody A. Charnow March 16, 2009

New findings raise questions about the practice of prescribing antibiotics to men prior to prostate biopsy if they have newly elevated PSA levels and a normal digital rectal examination (DRE).
 

After the PSA Cutoff Era: The Importance of Context

J. Stephen Jones, MD, FACS March 01, 2009

About two years ago, having recognized that the prostate-specific antigen (PSA) cutoff level of 4.0 ng/mL did not always assist in accurately categorizing a man's risk for prostate cancer, we began to eliminate this—or any—artificial cutoff defining a "normal" PSA value.
 

Study: Salvage Prostatectomy Is Effective

Jody A. Charnow January 30, 2009

SALVAGE RADICAL prostatectomy (SP) is an effective treatment for prostate cancer patients who experience local failure following radiotherapy, according to researchers.
 

Urine Assay for Prostate Cancer Advances

Rosemary Frei, MSc January 23, 2009

SAN DIEGO—A commercial assay may prove to be valuable for determining which men with elevated prostate-specific antigen (PSA) levels or an abnormal digital rectal exam (DRE) are likely to have prostate cancer and hence should undergo biopsy.
 

Popular Drugs Found to Decrease PSA Levels

Myra Dembrow December 08, 2008

Two of the most common classes of medication — statins and nonsteroidal anti-inflammatory drugs (NSAIDs) — may compromise cancer screenings by lowering serum prostate-specific antigen (PSA) levels, according to two studies.
 

A Clinical Dilemma: What is Normal?

Delicia Honen Yard December 08, 2008

The concept of what is "normal" enters into nearly every aspect of clinical decision making. For physicians to declare something abnormal and make a diagnosis, they must first know what normal is.
 

ADT-Related Anxiety Linked to Elevated PSA

Rosemary Frei, MSc November 14, 2008

Men with elevated serum PSA levels prior to beginning androgen deprivation therapy (ADT) for prostate cancer are nearly eight times more likely to experience anxiety after starting ADT, researchers reported.
 

Radiation Aids PCa Survival

John Schieszer November 01, 2008

BOSTON—Men with locally advanced prostate cancer can reduce their risk of dying from the malignancy by adding radiation treatment to anti-androgen therapy, according to a study that researchers believe to be the first of its kind.
 

Latest News

Popular Topics
Acute Kidney Injury Adrenal Gland Bladder Cancer BPH Brachytherapy Cardiovascular Disease Chronic Kidney Disease CKD Diabetes Diabetes Mellitus Dialysis End-stage Renal Disease Epidemiology FSGS Hemodialysis Hypertension Hypogonadism Infection Kidney Cancer Kidney Disease Obesity Prostate Cancer Renal Cell Carcinoma Reproductive Medicine Transplantation